April 13, 2006 — The US Food and Drug Administration (FDA) has approved a once-daily methylphenidate transdermal system for the treatment of attention-deficit/hyperactivity disorder in children aged 6 to 12 years

Daytrana (methylphenidate transdermal system, Shire) Approved by the FDA for the treatment of attention deficit hyperactivity disorder (ADHD). Oral methylphenidate drugs should be considered prior to selecting Shire / Noven’s Daytrana patch for treatment of attention deficit / hyperactivity disorder due to concerns about skin sensitization.

Daytrana dosage
Daytrana is a once daily transdermal patch formulation of methylphenidate. Daytrana is available in 10 mg, 15 mg, 20 mg and 30 mg dosage strengths. It is advisable to always start with a low dose of Daytrana, such as the 10 mg to see if there are side effects to Daytrana before taking higher amounts.

Daytrana Research
A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD.
Journal of Attention Disord. 2006 Feb;9(3):476-85. McGough JJ, Wigal SB, Abikoff H, Turnbow JM, Posner K, Moon E. University of California, Los Angeles, Semel Institute for Neuroscience and Human Behavior, 90095,
This study evaluates the efficacy, duration of action, and tolerability of methylphenidate transdermal system Daytrana in children with ADHD. Participants were dose optimized over 5 weeks utilizing Daytrana patch doses of 10, 16, 20, and 27 mg applied in the morning and worn for 9 hours. Following optimization, 80 participants were randomized to 1 week of Daytrana or placebo followed by 1 week of the opposite treatment. RESULTS: Daytrana was well tolerated and displayed significant improvement compared with placebo. CONCLUSIONS: Treatment with Daytrana resulted in statistically significant improvements on all efficacy measures. Time course and therapeutic effects of Daytrana suggest that this novel methylphenidate delivery system is an efficacious once-daily treatment for ADHD.